INSM vs VERX: How Insmed Incorporated and Vertex Compare (2026)

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: VERX is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. INSM and VERX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined INSM and VERX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Insmed Incorporated (Nasdaq: INSM) is a Bridgewater, New Jersey-based global biopharmaceutical company focused on serious and rare diseases, organized across three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. Its commercial portfolio consists of two products. ARIKAYCE (amikacin liposome inhalation suspension) is an inhaled antibiotic approved in the United States, European Union, and Japan for refractory Mycobacterium avium complex (MAC) lung disease, a rare, chronic, and potentially fatal bacterial infection of the lungs. BRINSUPRI (brensocatib), a once-daily oral DPP1 inhibitor licensed from AstraZeneca in 2016, received FDA approval in August 2025 and European Commission approval in November 2025 as the first and only dedicated treatment for non-cystic fibrosis bronchiectasis, a progressive condition affecting an estimated 500,000 people in the United States alone. The pipeline includes TPIP, an inhaled treprostinil prodrug in Phase 3 development for pulmonary hypertension indications, as well as early-stage gene therapy programs in Duchenne muscular dystrophy and ALS. The company generates revenue entirely from product sales; it does not pay a dividend and remains net unprofitable as it invests heavily in commercial launches and clinical development.

Full INSM guide

Vertex, Inc. (NASDAQ: VERX) is a global provider of indirect tax software, content, and services that help large and mid-size enterprises calculate, collect, and report taxes such as sales and consumer use tax, value added tax (VAT), and payroll-related indirect taxes. Its core O Series platform plugs into the ERP, e-commerce, procurement, and billing systems that big companies already run (SAP, Oracle, Workday, Salesforce and others) and applies a continuously updated database of tax rules across thousands of jurisdictions so that the correct tax is applied on every transaction. Founded in 1978 and public since 2020, Vertex serves roughly 4,900 direct customers, many of them large multinationals, and earns the bulk of its revenue from recurring software subscriptions plus related services, with annual recurring revenue per customer of about $137,867 as of late 2025.

Full VERX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• INSM drivers: BRINSUPRI as a potential blockbuster in a first-mover market; ARIKAYCE growth and label expansion potential.
• VERX drivers: Recurring, mission-critical tax compliance; Cloud migration and higher-value expansion.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The stock carries a demanding valuation, trading at roughly 26x trailing price-to-sales as of late June 2026, a meaningful premium to biotech peers, which means any shortfall in BRINSUPRI uptake or payer coverage could trigger sharp multiple compression. For VERX, vertex shares fell roughly 70% over the year to mid-2026, driven by deteriorating key performance indicators in late 2025, extended sales cycles, and reduced growth and margin expectations, so momentum and sentiment have been sharply negative.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick INSM if you believe its drivers more; VERX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the INSM and VERX guides.

INSM. Insmed does not yet report a meaningful P/E ratio because the company remains net unprofitable, investing heavily in the BRINSUPRI commercial launch and clinical pipeline. Revenue growth is accelerating sharply: Q1 2026 revenues of $306 million exceeded Q1 2025 revenues of $92.8 million by more than 230%, driven by BRINSUPRI reaching $207.9 million in only its second full quarter on the market. The elevated price-to-sales multiple reflects market expectations that BRINSUPRI will scale toward blockbuster status, and investors are effectively paying a premium for a company that analysts do not expect to reach consensus profitability until approximately 2028.

VERX. As of July 2026, Vertex traded at a market cap of about $2.0 billion after losing roughly 70% of its value over the prior year, even though revenue kept growing and adjusted EBITDA was rising. The stock now trades on a much lower revenue multiple than it did at its peak, reflecting reset growth and margin expectations. Whether that repricing is an opportunity or a warning depends on whether growth stabilizes and the 2026 cost plan delivers the promised savings.

Headline figures (approximate, 2026-06-25): INSM shows full-year 2025 revenue ~$606 million, q1 2026 revenue (most recent quarter) ~$306 million, 2026 revenue guidance (brinsupri alone) at least $1 billion, net loss per share (q1 2026) -$0.76; VERX shows market cap ~$2.0 billion, revenue (ttm) ~$775 million, fy2025 revenue ~$752 million, fy2026 revenue guidance ~$823 to $831 million.

INSM and VERX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined INSM and VERX exposure against your real portfolio. It is not an investment adviser.